Justine Abella Ross

Justine Abella Ross

Auto-generated profile, based on publicly available information

Justine Abella Ross

City of Hope

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JRJustine Abella Ross
Justine Abella Ross
KKKellie Komoda
Kellie Komoda
SPSumanta K Pal
Sumanta K Pal
JDJana Kubrin Dickter
Jana Kubrin Dickter
Ravi SalgiaRavi Salgia
Ravi Salgia
SDSanjeet Dadwal Dadwal
Sanjeet Dadwal Dadwal
Background: Immune checkpoint inhibitors (ICIs) are targeted cancer therapies regarded to have less toxicity than chemotherapy. Immune‐related adverse events (irAEs) of ICIs are well described in the literature but limited data exist on their infectious complications. The objective is to describe the spectrum and risk factors for developing serious infections in patients receiving ICIs.Methods: Retrospective review of patients with melanoma, renal cell carcinoma, or nonsmall‐cell lung cancer on nivolumab, pembrolizumab, and/or ipilimumab from January 1, 2017 to November 30, 2017. Exclusion: receipt of less than two ICI doses or history of other malignancy. Characteristics: age, sex, prior chemotherapy, steroid use, and temozolomide or infliximab use. Data identified from microbiology, radiography, serology, or physician note documentation. Serious infection is defined as infections requiring hospitalization and/or IV antibiotics from initiation of ICI until the end of the study period.Results: One hundred and eleven pts received ICIs. Suspected or confirmed bacterial infections occurred in 24% (27/111) with 8% (9/111) confirmed bacterial cultures. The overall serious infection rate was 14% (16/111) with 25% (4/16) confirmed bacterial cultures. Suspected or confirmed infection sites: genitourinary 20% (22/111), pneumonia 5% (7/111), skin/soft tissue 7% (8/111). Noninfectious pneumonitis (NIP) occurred in 5% (5/111). No association regarding the risk of infection between the type of malignancy and ICI used. Steroid use was the only risk factor significantly associated with serious infection: 12/16 (75%) on steroids versus 27/95 (28.4%) without steroid use (p = 0.0003).Conclusion: The rate of serious infection with ICI was higher in our study compared with previous reports of pts treated with melanoma. Infectious complications are encountered with ICIs and correlate with steroid use.

24 March 2020 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
JRJustine A. Ross
Justine A. Ross
NKNicole A. Karras
Nicole A. Karras
BTBernard Tegtmeier
Bernard Tegtmeier
CYChris Yamada
Chris Yamada
JCJason Chen
Jason Chen
SDSanjeet Dadwal
Sanjeet Dadwal
Purpose: Primary objective is to evaluate safety of isavuconazonium sulfate (ISA) in pediatrics below 18 years old. Exploratory endpoint includes mortality due to probable and proven invasive fungal infection (IFI) and overall morality in this population. Patients and Methods: Retrospective review of patients below 18 years receiving ISA for ≥7 days for possible, probable, or proven IFI or prophylaxis between June 2015 and March 2018. Descriptive analysis performed to calculate median, frequency, and percentages. Results: Safety analysis included 18 patients and a subgroup of 11/18 patients were assessed for efficacy. Median age 12.5 years (4 to 17 y), median weight 50.25 kg (19 to 118 kg), 50% male, 77% acute leukemias, 94% hematopoietic cell transplant recipients, 50% matched unrelated donors and 78% in remission. Elevated alanine aminotransferase 3 times baseline within 30 days of ISA occurred in 22% (4/18). No patients had elevated bilirubin or increase in serum creatinine. All-cause mortality at 90 days was 22% (4/18) and 27% (3/11) in patients with probable or proven IFI. Clinical response rates: 14-day: 45% (5/11) partial, 27% (3/11) stable; 30-day: 45% (5/11) partial, 36% (4/11) stable; 90-day: 54% (6/11) had either partial (n=3) or complete (n=3) response to ISA. Conclusions: ISA is safe in pediatric patients for the treatment of IFI. Prospective, randomized controlled trials are warranted to determine efficacy and safety of ISA in pediatric patients with hematologic malignancies and hematopoietic cell transplant.

12 January 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
JDJana Kubrin Dickter
Jana Kubrin Dickter
JRJustine A. Ross
Justine A. Ross
JZJasmine M. Zain
Jasmine M. Zain
BTBernard R. Tegtmeier
Bernard R. Tegtmeier
BLBrian V. Lee
Brian V. Lee
SDSanjeet Dadwal Dadwal
Sanjeet Dadwal Dadwal
What is known and objective Management of pan-resistant cytomegalovirus infection (CMVi) requires a multifaceted approach, including host defence optimization by reducing immunosuppression, and standard or experimental antiviral therapy. Case description A 36-year-old man with anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma, who underwent allogeneic haematopoietic stem cell transplant (alloHCT) with resultant graft-versus-host disease treated with immunosuppressive therapy, developed pan-resistant CMVi. He was successfully treated with combination therapy of maribavir and letermovir. What is new and conclusion Combination therapy, used for other infections to prevent cross-resistant, may apply for CMVi.

10 June 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
JDJana Kubrin Dickter
Jana Kubrin Dickter
ANAbigail L. Martin Np
Abigail L. Martin Np
SHStephanie Ho
Stephanie Ho
JRJustine A. Ross
Justine A. Ross
GDGeoffrey P. Shouse Do
Geoffrey P. Shouse Do
What is known and objective Treatment for diffuse large B-cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug-drug interactions, toxic effects and ART resistance must be considered. Case description A 40-year-old man with drug-resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. During chemotherapy, darunavir/cobicistat was held and ibalizumab-uiyk was started to ensure he was on three active HIV medications. What is new and conclusion Ibalizumab-uiyk has no known drug-drug interactions and may be used as bridge therapy for patients with drug-resistant HIV undergoing chemotherapy.

23 July 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JRJustine Abella Ross
Justine Abella Ross
BLBrian Lee
Brian Lee
HMHuiyan Ma
Huiyan Ma
BTBernard Tegtmeier
Bernard Tegtmeier
DNDeepa Nanayakkara
Deepa Nanayakkara
SDSanjeet Dadwal Dadwal
Sanjeet Dadwal Dadwal
Continuing antifungal prophylaxis (AFPx) to prevent invasive mold infections (IMIs) in recipients of allogeneic hematopoietic cell transplantation (alloHCT) after primary hospital discharge from alloHCT admission varies among transplant centers despite recommendations to continue prophylaxis through day +75. Characteristics driving AFPx prescribing at hospital discharge and outcomes are unknown. In this retrospective analysis, we reviewed patients continuing AFPx vs no AFPx at hospital discharge. We included patients with a hospital stay ≥7 days and ≤40 days. We excluded patients with a history of IMI prior to alloHCT, new IMI during admission, or death prior to discharge. Our primary objective was incidence of probable or proven IMI per the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Our secondary objectives were nonrelapse mortality at day +100, overall survival at day +100, and characteristics driving AFPx discontinuation at hospital discharge. Of the 430 patients identified, 387 met inclusion criteria. At discharge, 56% (217/387) continued AFPx, and 44% (170/387) had no AFPx. At day +100, 3 probable IMI cases occurred in the group with continued AFPx vs 1 probable IMI case in the no-AFPx group (no proven IMI). Univariate analysis showed no difference in cumulative incidence of probable IMI (P = .440), nonrelapse mortality (P = .072), and overall survival (P = .855) between groups. Multivariable logistic regression demonstrated that patients were less likely to continue AFPx if they had a diagnosis other than acute myeloid leukemia, a length of stay ≤30 days, acute graft-vs-host disease grade 0 or 1, and corticosteroid use ≤5 days. There was no difference in probable IMI at day +100 after alloHCT based on continuing vs discontinuing AFPx at hospital discharge after alloHCT admission supporting a risk-adapted prophylaxis approach.

13 November 2025 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
SKSara Kurd-Misto
Sara Kurd-Misto
JRJustine Ross
Justine Ross
SBSamantha Shannon Bastow
Samantha Shannon Bastow
KYKalvin Yu
Kalvin Yu
SDSanjeet Dadwal
Sanjeet Dadwal
Objective: To evaluate the incidence of hospital-onset bacteremia and fungemia (HOB) among solid organ malignancy (SOM), hematologic malignancy (HM), and hematopoietic cell transplant (HCT) therapy patients at a large cancer care center. Methods: A single-center, observational, retrospective analysis was conducted for hospitalizations between January 1, 2018, and September 30, 2024, to identify patients with a first positive blood culture on or after day four of hospitalization. Hospitalizations were grouped into three categories: SOM, HM with HCT, and HM without HCT. The primary objective was to study the incidence of HOB. Secondary objectives: identification of risk factors for HOB events and pathogens associated with HOB events. Results: In 45,896 admissions, 1,470 HOB events were identified (incidence: 3.2%). The incidence of HOB was highest in the HM/HCT cohort (3.8%), followed by HM without HCT (2.3%) and SOM (0.9%). Risk factors of HOB identified included HM (OR 1.49), hospitalization within the past 90 days (OR 1.50), length of stay greater than or equal to 30 days (OR 6.74), intensive care unit (ICU) admission (OR 4.06), development of a CAUTI during admission (OR 23.23), or presence of a central line (OR 51.61). The most common pathogens were Escherichia coli (20.1%), coagulase-negative Staphylococci (19.0%), and Viridians streptococci (11.3%). Conclusion: This study highlights the high incidence of HOB among cancer and HCT patients. The risk factors and differential rates of HOB in subpopulations of this demographic may help to inform targeted infection prevention efforts in cancer centers.